Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice

Neoplasia

Volumn 6, Issue 6, 2004, Pages 821-830

  Kelavkar, Uddhav P ^a,e   Glasgow, Wayne ^b   Olson, Sandra J ^c   Foster, Barbara A ^d   Shappell, Scott B ^c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Linoleic acid; Lipoxygenase; Mouse model; Prostate cancer; TRAMP

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 15 LIPOXYGENASE 1; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONIC ACID; CORIOLIC ACID; LEUKOCYTE TYPE 12 LIPOXYGENASE; LINOLEIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID METABOLISM; GENE CONTROL; GENE FUNCTION; GENETIC ENGINEERING; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MOUSE; NONHUMAN; ORTHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REACTION ANALYSIS;

EID: 11144350221     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04286     Document Type: Article

References (44)

1. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, and Cardiff RD (2004). Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64, 2270-2305.
2. Gupta S, Hastak K, Ahmad N, Lewin JS, and Mukhtar H (2001). Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 98, 10350-10355.
3. Wechter WJ, Leipold DD, Murray ED Jr, Quiggle D, McCracken JD, Barrios RS, and Greenberg NM (2000). E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 60, 2203-2208.
4. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, and Elgavish A (2001). Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 61, 6777-67782.
5. Abate-Shen C and Shen MM (2002). Mouse models of prostate carcinogenesis. Trends Genet 18, S1-S5.
6. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, and Rosen JM (1995). Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92, 3439-3443.
7. Gingrich JR, Barrios RJ, Foster BA, and Greenberg NM (1999). Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 2, 70-75.
8. Kasper S, Sheppard PC, Van Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, and Matusik RJ (1998). Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 78, 319-333.
9. Masumori N, Tsuchiya K, Tu WH, Lee C, Kasper S, Tsukamoto T, Shappell SB, and Matusik RJ (2004). An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J Urol 171, 439-442.
10. Ghosh J and Myers CE (1997). Arachidonic acid stimulates prostate cancer cell growth critical role of 5-lipoxygenase. Biochem Biophys Res Commun 235, 418-423.
11. Gao X, Grignon DJ, Chbihi T, Zacharek A, Chen YQ, Sakr W, Porter AT, Crissman JD, Pontes JE, Powell IJ, et al. (1995). Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 46, 227-237.
12. Spindler SA, Sarkar FH, Sakr WA, Blackburn ML, Bull AW, LaGattuta M, and Reddy RG (1997). Production of 13-hydroxyoctadecadienoic acid (13-HODE) by prostate tumors and cell lines. Biochem Biophys Res Commun 239, 775-781.
13. Kelavkar UP, Cohen C, Kamitani H, Eling TE, and Badr KF (2000). Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging. Carcinogenesis 21, 1777-1787.
14. Kelavkar UP, Nixon J, Cohen C, Dillehay D, Eling TE, and Badr KF (2001). Overexpression of 15-lipoxygenase-1 (15-LO-1) in PC-3 human prostate cancer cells causes aggressive tumorigenesis. Carcinogenesis 22, 1765-1773.
15. Shappell SB, Boeglin WE, Olson SJ, Kasper S, and Brash AR (1999). 15-Lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 155, 235-245.
16. Shappell SB, Manning S, Boeglin WE, Guan YF, Roberts RL, Davis L, Olson SJ, Jack GS, Coffey CS, Wheeler TM, Breyer MD, and Brash AR (2001). Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 3, 287-303.
17. Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, Smith JA Jr, and Shappell SB (2000). Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 31, 1146-1154.
18. Tang S, Bhatia B, Maldonado CJ, Yang P, Newman RA, Liu J, Chandra D, Traag J, Klein RD, Fischer SM, Chopra D, Shen J, Zhau H, Chung LW, and Tang DG (2002). Evidence that Arachidonate 15-lipoxygenase 2 is a negative cell-cycle regulator in normal prostate epithelial cells. J Biol Chem 277, 16189-16201.
19. Smith WL, Garavito RM, and DeWitt DL (1996). Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271, 33157-33160.
20. O'Neill GP and Ford-Hutchinson AW (1993). Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330, 156-160.
21. Hussain T, Gupta S, and Mukhtar H (2003). Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191, 125-135.
22. Dunn JE (1975). Cancer epidemiology in populations of the United States-with emphasis on Hawaii and California-and Japan. Cancer Res 35, 3240-3245.
23. Haenszel W and Kurihara M (1968). Studies of Japanese migrants: I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40, 43-68.
24. Fleshner N, Bagnell PS, Klotz L, and Venkateswaran V (2004). Dietary fat and prostate cancer. J Urol 171, S19-24.
25. Brash AR (1999). Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 274, 23679-23682.
26. Chen X-S, Kurre U, Jenkins NA, Copeland NG, and Funk CD (1994). cDNA cloning, expression, mutagenesis of C-terminal isoleucine, genomic structure, and chromosomal localizations of murine 12-lipoxygenases. J Biol Chem 269, 13979-13987.
27. Reddy N, Everhart A, Eling T, and Glasgow W (1997). Characterization of a 15-lipoxygenase in human breast carcinoma BT-20 cells stimulation of 13-HODE formation by TGF alpha/EGF. Biochem Biophys Res Commun 231, 111-116.
28. Bertomeu MC, Gallo S, Lauri D, Haas TA, Orr FW, Bastida E, and Buchanan MR (1993). Interleukin 1-induced cancer cell/endothelial cell adhesion in vitro and its relationship to metastasis in vivo role of vessel wall 13-HODE synthesis and integrin expression. Clin Exp Metastasis 11, 243-250.
29. Buchanan MR, Horsewood P, and Brister SJ (1998). Regulation of endothelial cell and platelet receptor-ligand binding by the 12- and 15-lipoxygenase monohydroxides. 12-15-HETE and 13-HODE. Prostaglandins Leukot Essent Fat Acids 58, 339-346.
30. Ikawa H, Kamitani H, Calvo BF, Foley JF, and Eling TE (1999). Expression of 15-lipoxygenase-1 in human colorectal cancer. Cancer Res 59, 360-366.
31. Kamitani H, Geller M, and Eling T (1998). Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation. J Biol Chem 273, 21569-21577.
32. Natarajan R and Nadler J (1998). Role of lipoxygenases in breast cancer. Front Biosci 3, E81-88.
33. Cesano A, Visonneau S, Scimeca JA, Kritchevsky D, and Santoli D (1998). Opposite effects of linoleic acid and conjugated linoleic acid on human prostatic cancer in SCID mice. Anticancer Res 18, 1429-1434.
34. Zock PL and Katan MB (1998). Linoleic acid intake and cancer risk a review and meta-analysis. Am J Clin Nutr 66, 142-153.
35. Kelavkar U and Badr K (1999). Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene. Proc Natl Acad Sci USA 96, 4378-4783.
36. Hsi LC, Wilson L, Nixon J, and Eling TE (2001). 15-Lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor gamma via the MAPK signaling pathway. J Biol Chem 276, 34545-34552.
37. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, Case T, Price J, Jack GS, Wheeler TM, Matusik RJ, Brash AR, and Dubois RN (2001). 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 61, 497-503.
38. Hsi LC, Wilson LC, and Eling TE (2002). Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate: alteration in PPARgamma. J Biol Chem 277, 40549-40556.
39. Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussalli MJ, Spindler SA, Greenson JK, Normolle D, Hasan AK, Lawrence TS, and Brenner DE (1999). Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis 20, 1985-1995.
40. Shappell SB, Olson SJ, Hannah SE, Manning S, Roberts RL, Masumori N, Jisaka M, Boeglin WE, Vader V, Dave DS, Shook MF, Thomas TZ, Funk CD, Brash AR, and Matusik RJ (2003). Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Res 63, 2256-2267.
41. Jisaka M, Kim RB, Boeglin WE, Nanney LB, and Brash AR (1997). Molecular cloning and functional expression of a phorbol ester-inducible 8S-lipoxygenase from mouse skin. J Biol Chem 272, 24410-24416.
42. Kaplan PJ, Mohan S, Cohen P, Foster BA, and Greenberg NM (1999). The insulin-like growth factor axis and prostate cancer: lessons from the TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) model. Cancer Res 59, 2203-2209.
43. Ruijter E, Van De Kaa C, Miller G, Ruiter D, DeBruyne F, and Schalken J (1999). Molecular genetics and epidemiology of prostate carcinoma. Endocrinol Rev 20, 22-45.
44. Kelavkar U and Cohen C (2004). 15-Lipoxygenase-1 expression upregulates and activates insulin-like growth factor-1 receptor in prostate cancer cells. Neoplasia 6, 41-52.